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Abstract
Background: Newborn screening (NBS) for cystic fibrosis (CF) not only identifies infants with a diagnosis of CF, but
also those with an uncertain diagnosis of cystic fibrosis (CF), i.e. CF transmembrane conductance regulator (CFTR)-
related metabolic syndrome (CRMS) or CF screen positive inconclusive diagnosis (CFSPID). These infants have an
uncertain long-term outcome and it is currently unclear around time of diagnosis, which infants are at higher risk of
later fulfilling a CF diagnosis. In this study, we hypothesised that immunoreactive trypsinogen (IRT) levels, used in
NBS as a marker of pancreatic disease and function, may reflect the degree of CFTR dysfunction in each individual
and therefore would help to identify those with CRMS/CSPID who are later at risk for meeting the criteria of CF.
Methods: In this longitudinal, prospective study, infants with CRMS/CFSPID and CF were recruited and followed in
9 CF clinics (Canada and Italy). We compared NBS IRT levels between CF and CRMS/CFSPID, and between children
with CRMS/CFSPID→CF and CRMS/CFSPID→CRMS/CFSPID during the period of June 2007 to April 2016.
Results: Ninety eight CRMS/CFSPID and 120 CF subjects were enrolled. During the study period, 14 (14.3%) CRMS/
CFSPID subjects fulfilled the diagnostic criteria for CF (CRMS/CFSPID→CF), while the diagnosis remained uncertain
(CRMS/CFSPID→ CRMS/CFSPID) in 84 (85.7%) subjects. Significantly higher NBS IRT concentrations (ng/ml) were
present in CF than CRMS/CFPSID (median (interquartile range): 143.8 (99.8–206.2) vs. 75.0 (61.0–105.9); P < 0.0001).
Infants with CRMS/CFSPID→CF (n = 14) had significantly higher NBS IRT concentrations (ng/ml) than CRMS/
CFSPID→ CRMS/CFSPID (n = 83) (median (interquartile range): 108.9 (72.3–126.8) vs. 73.7(60.0–96.0); P = 0.02).
Conclusions: Amongst infants who tested positive on NBS for CF, there is a gradation of elevated NBS IRT
concentrations. Infants with CF have higher NBS IRT levels than CRMS/CFPSID, and higher NBS IRT concentrations
were present in infants with CRMS/CFSPID→CF than CRMS/CFSPID→ CRMS/CFSPID. NBS IRT concentrations, in
concert with other factors, may have the potential to predict the likelihood of CF amongst infants with CRMS/
CFSPID.
Keywords: CF screen positive inconclusive diagnosis (CFSPID), CFTR-related metabolic syndrome (CRMS), Newborn
screening, Sweat test, Trypsinogen
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Background
Cystic fibrosis (CF) is a life-limiting, autosomal recessive
disease caused by pathogenic mutations in the gene en-
coding the CF transmembrane conductance regulator
(CFTR) protein. With the availability and expansion of
newborn screening (NBS) programs for CF, a new sub-
group of infants with a positive NBS result, but an incon-
clusive diagnosis of CF has emerged. These infants, who
have an uncertain long-term outcome (CF vs. CFTR-
related disorder vs. healthy), have been designated as CF
transmembrane conductance regulator (CFTR)-related
metabolic syndrome (CRMS) or CF screen positive incon-
clusive diagnosis (CFSPID) (also known as CRMS/CFSPID
in the most recent international joint consensus) [1, 2].
Since the first report of newborns with CF having ele-
vated immunoreactive trypsinogen (IRT) levels [3], IRT
measurements have become central to NBS protocols
worldwide. Immunoreactive trypsinogen levels reflect se-
verity of pancreatic disease and pancreatic function [4–6],
which in turn is associated with the severity of the CFTR
gene defect. Higher and more rapid decline in IRT levels
are associated with more severe CFTR variants (Class I-
III), while lower levels are observed with less severe vari-
ants (Class IV-VI) [7–9]. There are also non-CFTR related
factors that can lead to a high neonatal IRT level, includ-
ing stressful or prolonged labor, Black race, and trisomy
21 [1]. We hypothesised that IRT levels may also reflect
the severity of the CFTR gene defect among children with
CRMS/CFSPID and would be different between children
with CRMS/CFSPID who subsequently met the criteria
for CF (CRMS/CFSPID→CF) and those whose diagnosis
remained uncertain (CRMS/CFSPID→ CRMS/CFSPID).
In this study, we compared IRT measured at NBS to dif-
ferentiate between CF and CRMS/CFSPID, and between
children with CRMS/CFSPID who subsequently met the
criteria for CF (CRMS/CFSPID→CF) and those whose
diagnosis remained uncertain (CRMS/CFSPID→ CRMS/
CFSPID).
Materials and methods
Subjects
A clinical-research protocol was developed to evaluate
and follow infants with a diagnosis of CRMS/CFSPID in
a prospective, longitudinal manner from 9 CF clinics
across 5 provinces in Canada (Ontario, British Columbia,
Alberta, Saskatchewan and Nova Scotia) and from Ver-
ona, Italy. Interim data for the period between June 2007
and April 2016 are reported here. Some of the subjects
have been previously reported in a separate study [10].
As part of NBS protocol, dried blood spots were col-
lected in the first 2 days of life. Analyses for IRT levels
from these samples were performed using the AutoDEL-
FIA method (Perkin-Elmer Life Sciences, Boston, USA).
Accordingly, an infant was considered to be NBS-
positive if: [1] IRT exceeded the site-specific cut-off, in
addition to at least one CFTR mutation (and/or raised
meconium lactase in Verona, Italy); or, [2] IRT exceeded
the 99.9th centile when no mutations were identified.
All infants who were identified as NBS-positive were
then referred to their local CF centre for sweat testing and
genotyping to determine whether they fulfilled the diag-
nostic criteria for CF (based on sweat chloride ≥60mmol/
L and/or CF-causing mutations on both alleles) [1].
This study was designed intentionally to reflect real-
life experiences in the CF clinic following a positive
NBS, during which parents/carers are informed as to
whether their infant has a diagnosis of CF or CRMS/
CFSPID (Fig. 1). For the latter, NBS-positive infants at
each centre were defined and entered into the study as
CRMS/CFSPID if they had at time of initial diagnosis an
indeterminate diagnostic outcome: [1] sweat chloride <
30mmol/L and 2 CFTR mutations with 0–1 CF-causing
CFTR mutations; or [2] sweat chloride 30–59mmol/L
and < 2 CF-causing CFTR mutations [1, 2]. As a com-
parator group, NBS-positive infants with a clear-cut
diagnosis of CF were also enrolled during the same
period. Infants who presented with meconium ileus and
fulfilled the diagnostic criteria for CF but were negative
on NBS (i.e. false negative) were also included as part of
the comparator group. Immunoreactive trypsinogen levels
obtained at NBS from NBS-positive infants with CRMS/
CFSPID and the comparator group of infants with CF
were collected for the study.
In our clinical-research protocol, subjects with CRMS/
CFSPID were clinically monitored and sweat tested 6
monthly in the first 2 years of life, and annually there-
after. Genotype information was obtained from NBS
mutation analyses. Subjects would undergo confirmatory
or further genotyping including CFTR gene sequencing,
especially for infants identified with less than two CFTR
mutations, usually prior to or at time of initial visit/diag-
nosis. Some of the CRMS/CFSPID subjects were subse-
quently reclassified as CF during the follow-up period
(CRMS/CFSPID→CF) if they at a later time point ful-
filled the diagnostic criteria for CF (either repeat sweat
chloride levels ≥60 mmol/L or abnormal genotype from
reassignment of previously indeterminate CFTR muta-
tion to “CF-causing”) i.e. the participant’s diagnostic
label and categorisation/re-categorisation in this pro-
spective study occurred months after the initial diagnosis
of CRMS/CFSPID and reflected real life reassignment of
diagnosis in clinical practice.
Statistical analysis
Descriptive statistics were presented according to the
normality of the data distribution. Continuous data was
presented as mean with standard deviation (SD) or me-
dian (interquartile range). Comparisons of NBS IRT
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concentrations were made using the Mann-Whitney test.
IBM SPSS Statistics (v 23.0; SPSS Inc., Chicago, Illinois)
were used. P-values < 0.05 were considered statistically
significant.
Results
Subject characteristics
Out of 218 subjects, 98 CRMS/CFSPID and 120 CF
subjects were enrolled. Among the 98 CRMS/CFSPID
subjects, 97 subjects had two mutations (no more
than one is CF-causing) with intermediate (n = 47) or
normal (n = 50) sweat chloride, and 1 subject had one
mutation (CF-causing) with intermediate sweat chlor-
ide. Mutations were either identified by NBS and/or
by confirmatory or further genotyping via the CF
clinic prior to or at time of initial visit/diagnosis.
During the study period, 14 (14.3%) CRMS/CFSPID
subjects fulfilled the diagnostic criteria for CF
(CRMS/CFSPID→CF) (Table 1 and Fig. 1), while the
diagnosis remained uncertain (CRMS/CFSPID→
CRMS/CFSPID) in 84 (85.7%) subjects. Among the 14
subjects with CRMS/CFSPID→CF, 10 had subsequent
elevations of sweat chloride levels ≥60 mmol/L (with
Fig. 1 Flowchart of the study summarising time of initial diagnosis and during the study follow-up period
Table 1 Characteristics of the 14 subjects with CFSPID who later fulfilled the diagnostic criteria for CF
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5 based on abnormal sweat test alone and 5 based on
both abnormal sweat test and genotype), and 4 based
on abnormal genotype alone (Table 1 and Fig. 1).
Among the 10 (out of 14) CRMS/CFSPID→CF pa-
tients who had abnormal sweat test levels (≥60 mmol/
L) on follow-up sweat testing, sweat chloride in-
creased to abnormal levels (mean [SD] of 68.30 [5.60]
mmol/L) at a mean (SD) age of 35.97 (21.43) months.
Immunoreactive trypsinogen levels
CRMS/CFSPID vs. CF
Infants with CF had significantly higher NBS IRT concen-
trations (ng/ml) (median (interquartile range)) than CRMS/
CFPSID (143.8 (99.8–206.2) vs. 75.0 (61.0–105.9); P <
0.0001) (Fig. 2).
CRMS/CFSPID→CF vs. CRMS/CFSPID→CRMS/CFSPID
Infants with CRMS/CFSPID→CF (n = 14) had signifi-
cantly higher NBS IRT concentrations (ng/ml) than
CRMS/CFSPID→ CRMS/CFSPID (n = 83) (median (inter-
quartile range): 108.9 (72.3–126.8) vs. 73.7(60.0–96.0); P =
0.02) (Fig. 3).
Further comparisons of the diagnostic outcomes are
shown in Fig. 4 based on initial sweat chloride levels (i.e.
done closest to NBS IRT) plotted against NBS IRT concen-
trations. While still overlapping with the CRMS/CFSPID→
CRMS/CFSPID cohort, infants with CRMS/CFSPID→CF
aggregate much closer to the CF cohort compared to the
overall CRMS/CFSPID→ CRMS/CFSPID group.
Discussion
The outcomes of infants with CRMS/CFSPID remain
uncertain. In this prospective longitudinal study of chil-
dren with CRMS/CFSPID, we identified the potential
role for NBS IRT as a biomarker to predict the likelihood
of having CF, with significantly different IRT levels be-
tween CF and CRMS/CFSPID, and also between CRMS/
CFSPID→CF and CRMS/CFSPID→ CRMS/CFSPID.
Our findings have biological plausibility. Among all
organ systems affected by CF disease, the exocrine pan-
creas serves as a phenotypic barometer of CFTR func-
tion and correlates well with the underlying genotype
[11–13]. The pancreatic insufficiency prevalence (PIP)
scores, based on the exocrine pancreatic phenotype, have
been shown to accurately distinguish the severity of dif-
ferent CFTR mutations [13]. In this study, we speculate
that IRT levels reflect the severity of pancreatic disease
and thus the severity of the underlying CFTR gene mu-
tation, with higher levels during the first few years of life
indicating more extensive pancreatic damage correlating
with more severe CFTR dysfunction, akin to higher IRT
levels in newborns with CF compared to non-CFs. Our
observations are in keeping with the association between
trypsinogen levels and the likelihood of having CF dis-
ease. However, this relationship is likely complex and
non-linear (as observed in Fig. 3). Furthermore, in two
Fig. 2 Comparison of newborn screening IRT levels between children with CF and CRMS/CFSPID
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separate studies, higher IRT levels were observed in chil-
dren with two CF-causing mutations compared to those
with either one mutation of varying clinical consequence
[7] or one non-CF causing mutation [8]. These findings
may be highly relevant clinically, as to date, aside from
diagnostic tests such as repeat sweat testing, extensive
genotyping or other functional CFTR testing, there is no
test that predicts or stratifies the risk of a later CF diag-
nosis following an initial diagnosis of CRMS/CFSPID. In
our previous study comparing CRMS/CFSPID→ CRMS/
CFSPID and CRMS/CFSPID→CF groups, there were no
significant differences in respiratory symptoms and
microbiology present [10]. Furthermore, IRT levels are
available at the time of diagnosis and thus limiting the
delays for risk stratification.
The diagnosis of CF is a dynamic and evolving process
among individuals with an indeterminate diagnosis.
There is continuous new discovery on the pathogenicity
of rare CFTR gene variants due to the ongoing efforts of
the CFTR2 project (http://cftr2.org). Furthermore, we
have previously demonstrated increases in sweat chlor-
ide concentrations over time in a subset of these individ-
uals [10]. In this current study, all 14 subjects with an
initial diagnosis of CRMS/CFSPID carried two CFTR
variants. Of those, 9 infants were later reassigned a diag-
nosis of CF (CRMS/CFSPID→CF) based on genotype; 5
of these 9 subjects also had increases in sweat chloride
levels above the 60mmol/L cut-off for CF diagnosis with
time while 4 of 9 subjects met the diagnosis of CF by
genotyping alone. Thus our experience provides support
for comprehensive genotyping in these individuals.
While many of these individuals already had their 2nd
CFTR mutation identified at time of assessment, these
mutations were not considered disease-causing until
later in the course of follow-up (with the roll-out of new
pathogenic CFTR variants by CFTR2). Since CFTR2 is
based on CF patient registries, it is worth noting though
that the primary goal of CFTR2 is to identify the most
common CF-causing variants rather than the most com-
mon non CF-causing variants, which is important in help-
ing distinguish CRMS/CFSPID→ CRMS/CFSPID from
CRMS/CFSPID→CF in the long-term. The remaining 5
subjects later fulfilled the diagnosis of CF based on sweat
testing alone. As this was a prospective, longitudinal study
all these 14 individuals were classified as CRMS/CFSPID
and not CF at the time of presentation and recruitment
(i.e. as it occurred in real-life clinical practice).
The present study has limitations. Our observations
are based on a small sample size, particularly with the
CRMS/CFSPID→CF cohort despite the multicentre and
multiyear approach of this study. Future efforts would
include confirming our observation in another cohort
and then either defining a sensitive IRT cut-off or identi-
fying trajectory of longitudinal IRT levels (i.e. levels over
time or age) to predict risk of developing CF based on a
larger sample size. Due to the multicentre and
Fig. 3 Comparison of newborn screening IRT levels between children with CRMS/CFSPID who subsequently met the criteria for CF (CFSPID→CF)
and those whose diagnosis remained uncertain (CFSPID→CFSPID)
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multinational approach, subjects were identified based
on different NBS protocols used. This study also did
not account for variability in IRT levels within and
across different provinces, and variations in IRT con-
centration among different races, birth weight and gesta-
tional age. However, the phenomenon of identifying
CRMS/CFSPID is ubiquitous irrespective of the variations
in NBS algorithms and despite this, there were significant
differences in IRT levels between the different cohorts of
children.
In conclusion, predicting outcomes of children with
CRMS/CFSPID remains a challenge, requiring careful
monitoring over time. Newborn screening IRT levels are
significantly different between children with CRMS/
CFSPID who subsequently met the criteria for CF and
those whose diagnosis remained uncertain, and may
have the potential to predict the likelihood of later ful-
filling the diagnostic criteria for CF.
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